Threats to the validity of observational studies on the effects of interventions raise questions about the appropriate role of such studies in decision making. Nonetheless, scholarly journals in fields such as medicine, education, and the social sciences feature many such studies, often with limited exploration of these threats, and the lay press is rife with news stories based on these studies. Consumers of these studies rely on the expertise of the study authors to conduct appropriate analyses, and on the thoroughness of the scientific peerreview process to check the validity, but the introspective and ad hoc nature of the design of these analyses appears to elude any meaningful objective assessment of their performance. Here, we review some of the challenges encountered in observational studies and review an alternative, data-driven approach to observational study design, execution, and analysis. Although much work remains, we believe this research direction shows promise.
INTRODUCTION
Consider the following article that recently appeared in the New England Journal of Medicine concerning the drug azithromycin and the risk of cardiovascular death (Ray et al. 2012) . The paper concludes that, relative to an alternative antibiotic, amoxicillin, "azithromycin was associated with an increased risk of cardiovascular death (hazard ratio, 2.49; 95% CI, 1.38 to 4.50; P = 0.002)" (p. 1881). The authors conducted their study in a database derived from patients enrolled in the Tennessee Medicaid program, identifying 347,795 people with prescriptions for azithromycin and 1,248,672 people with prescriptions for amoxicillin.
Patients, providers, payers, and regulators rely on hundreds or even thousands of observational studies like this to make critical decisions. Nearly 80,000 observational studies were published in the decade 1990-2000 (Naik 2012 ). In the following decade, the number of studies grew to more than 260,000. Because Ray et al.'s (2012) study was not a randomized clinical trial, two challenges arise. First, the estimated rate ratio may be biased, which is a concern about all observational studies and one that commands most of the discussion section of each paper. That is, this type of analysis could systematically produce rate ratio estimates that are on average too high or too low. Second, the confidence interval might be badly calibrated. That is, the 95% confidence intervals produced by this type of analysis might, for instance, contain the true treatment effect only 50% of the time, instead of the expected 95%. For the example above, a debiased estimate may be 1.0 or 5.0 instead of 2.49. Perhaps the true 95% confidence interval should be 0.50-5.00 instead of 1.38-4.50. What would have happened if different investigators had studied the same question in a different database or applied a different analysis method to the same data? How is this information supposed to contribute to our evidence base? The epidemiologic and statistical literatures acknowledge that observational studies can produce biased and miscalibrated estimates but provide little guidance on how to quantify the extent of the problem. One exception is the highly cited work of Ioannidis (2005) , but even this effort at quantification draws mainly on hypothetical scenarios rather than empirical investigation. This paper reviews the ongoing work of the Observational Medical Outcomes Partnership (OMOP; http://omop.org) that attempts to shed light on some of these questions (Stang et al. 2010) . Our work to date has focused on four primary objectives. First, we have attempted to establish the operating characteristics of current standard observational study methods . Specifically, we have characterized bias, coverage of confidence intervals, and ability to discriminate between positive and negative controls for thousands of implementations of epidemiologic designs across 10 databases for hundreds of drug-outcome pairs. We have collaborated with investigators in a network of European databases who have conducted similar methodological research and have replicated the OMOP experiment (Schuemie et al. 2012) . Our results suggest that bias is a significant problem in many contexts, and that statistical measurements, such as confidence intervals and p-values, are substantially invalid, empirically confirming Ioannidis's findings. Second, we have documented the substantial variability that results when identical analyses are conducted against different databases or when specific decisions within an analysis, such as time at risk or confounding adjustment strategy, are modified. Third, we have developed data-driven approaches to remove bias and provide confidence intervals and p-values with close to nominal operating characteristics (e.g., 95% confidence intervals that contain the true effect size 95% of the time). Fourth, we have developed an approach to observational study design that yields known operating characteristics.
We view our work as taking early steps toward a rigorous, well-characterized, evidence-based approach to estimating effects in observational studies. Much work remains to be done. We believe the use of observational healthcare data could be transformed from episodic investigations based on presumed expert opinion and anecdote into a comprehensive system that can proactively explore, monitor, and evaluate human disease, health service utilization, and the effects of all medical products across a large array of health outcomes of interest (HOI), in/near real time.
Our work to date focuses specifically on drug safety, an issue of particular current concern. The US Food and Drug Administration (FDA) Amendments Act of 2007 required the establishment of an active postmarket risk identification and analysis system with access to patient-level observational data from 100 million lives by 2012 (http://www.fda.gov/Safety/ FDAsSentinelInitiative/default.htm). However, we believe our work is applicable to the many other applications of observational studies to estimate the effects of interventions, including the emerging interest in comparative effectiveness research.
Section 2 reviews the literature to highlight challenges in observational data analysis. Section 3 reviews the results of a subset of OMOP experiments that consider method performance for four specific outcomes in five large-scale observational databases. Section 4 describes an approach to calibrating the statistical outputs of an observational study. Specifically, we describe an approach for calculating calibrated p-values that provide desired false positive rates. Section 5 sets forth a recipe for observational studies that delivers known performance characteristics. We conclude with a discussion.
CHALLENGES IN OBSERVATIONAL ANALYSIS
Prior to regulatory approval, while a drug is in development, randomized clinical trials represent the primary sources of safety information. Such experiments are generally regarded as the highest level of evidence, leading to an unbiased estimate of the average treatment effect (Atkins et al. 2004) . Unfortunately, most trials suffer from insufficient sample size and lack of applicability to reliably estimate the risk of many potential safety concerns for the target population (Berlin et al. 2008 , Waller & Evans 2003 . Even if one leverages meta-analytic tools, rare side effects, longterm outcomes (both positive and negative), and effects in patients with comorbidities may still be unknown when a product is approved because of the relatively small size and short duration of clinical trials. For products intended to treat chronic, non-life-threatening conditions that occur in large populations, the International Conference for Harmonisation (Azoulay et al. 2012 ) recommends a baseline safety database that involves at least 1,500 patients on average with at least a 6-month exposure time to reliably (i.e., 95% of the time) identify events happening at the 1% level (US Food Drug Admin. 1999) . In other words, events that occur less frequently than 1 in 100 patients are not expected to be detected under this recommendation.
Observational studies represent an alternative approach to evaluating drug safety questions and can give us the necessary information about drug effects to support clinical decision making. Observational studies provide empirical investigations of exposures and their effects, but differ from experiments in that assignment of treatment to subjects is not controlled (Rosenbaum 2002) . Observational studies can be based on many forms of epidemiologic investigation, using a variety of methods for data collection, applying alternative study designs, and employing a range of analysis strategies (Hartzema et al. 1999 (Hartzema et al. , 2008 Jewell 2004; Rothman 2002; Rothman et al. 2008; Szklo & Nieto 2007) . These studies can range from population-based cohort studies with prospective data collection to targeted disease registries to retrospective case-control studies.
One type of resource that has provided fertile ground for epidemiologic investigation has been observational healthcare databases. Administrative claims and electronic health record (EHR) databases have been actively used in pharmacoepidemiology for more than 30 years (Strom 2005) but have seen increased use in the past decade owing to greater availability at lower costs and technological advances that made computational processing on large-scale data more feasible.
Many such databases contain large numbers of patients that make possible the examination of rare events and specific subpopulations that previously could not be studied with sufficient power (Rockhill et al. 1998 , Rodriguez et al. 2001 . Because the data reflect healthcare activity within a real-world population, they offer the potential to complement clinical trial results. Long-term longitudinal capture of data in these sources can also enable studies that monitor the performance of risk management programs or other interventions over time (Weatherby et al. 2002) .
Administrative claims databases have been the most actively used observational healthcare data source. These databases typically capture data elements used within the reimbursement process, as providers of healthcare services (e.g., physicians, pharmacies, hospitals, and laboratories) must submit encounter information to enable payment for their services (Hennessy 2006) . The submitted information commonly includes pharmacy claims for dispensing of prescription drugs (e.g., the drug dispensed, the dispensing date, and the number of days of drug supply) and medical claims (inpatient and outpatient) that detail the dates and types of services rendered. Medical claims typically contain diagnosis codes used to justify reimbursement for the services provided. Information on over-the-counter drug use and in-hospital medication is usually unavailable, and the patient's compliance with the prescription is generally unknown (Suissa & Garbe 2007) .
EHRs generally contain data captured at the point of care, with the intention of supporting the process of clinical care as well as justifying reimbursement and providing data for quality measurement. A patient record may include demographics (birth date, gender, and race), height and weight, and family and medical history. Many EHR systems support provider entry of diagnoses, signs, and symptoms and also capture other clinical observations, such as vital signs, laboratory results, and imaging reports. Beyond those, EHRs may often contain findings of physical examinations and the results of diagnostic tests . EHR systems usually also have the capability to record other important health status indications, such as alcohol use and smoking status (Lewis & Brensinger 2004) , but the data may be missing in many patient records (Hennessy 2006) . As a result of discontinuous care within the US healthcare system, a patient may have multiple EHRs scattered across the providers the individual has seen, but rarely are those records integrated, nor can they usually be linked, so each EHR record reflects a different and incomplete perspective of that person's healthcare experience. Recent efforts to advance health information exchange aim to reduce this fragmentation.
Neither administrative claims nor EHRs represent the ideal information required to assess a particular effect. For example, diagnoses recorded on medical claims are used to support justification for the payment for a given visit or procedure; a given diagnosis could represent the condition that the procedure was used to rule out or could be an administrative artifact (e.g., the code used by a medical coder to maximize the reimbursement amount). Some diagnosis codes have been studied through source record verification and have demonstrated adequate performance characteristics (Donahue et al. 1997 , García Rodríguez & Pérez Gutthann 1998 , Hennessy et al. 2009 , Lee et al. 2005 , Miller et al. 2008 , Pladevall et al. 1996 , So et al. 2006 , Tunstall-Pedoe 1997 , Varas-Lorenzo et al. 2008 , Wahl et al. 2010 , Wilchesky et al. 2004 , whereas other conditions and systems provide less certainty (Harrold et al. 2007 , Leonard et al. 2008 , Lewis et al. 2007 , Strom 2001 . Limitations exist in EHR systems as well, in which, apart from concerns about incomplete capture, data may be artificially manipulated to serve clinical care (e.g., an incorrect diagnosis recorded to justify a desired medical procedure). Most systems have insufficient processes to evaluate data quality a priori, requiring intensive work on the part of the researcher to prepare the data for analysis (Hennessy et al. 2007 ). To estimate potential drug exposures, for example, researchers can make inferences in administrative claims sources based on pharmacy dispensing records, whereas inferences for EHR systems rely on patient self-report and physician prescribing orders (Hennessy 2006) . Neither approach reflects the timing, dose, or duration of drug ingested, so assumptions are required in interpretation of all study results.
The principal concern for all observational studies, which is of particular relevance in observational database evaluation, is the potential for bias. illustrated some of the potential sources of bias that are introduced throughout the data capture process for both administrative claims and EHRs. An observational study is biased if the treated and control groups differ prior to treatment in ways that can influence the outcome under study (Rosenbaum 2002) . Several forms of bias can arise in the design and conduct of an observational study. In the context of drug safety analyses, one of the most challenging issues is confounding by indication, i.e., a situation in which the indication for the medical product is also an independent risk factor for the outcome (Walker 1996) . Therefore, a medical product can spuriously appear to be associated with the outcome when no appropriate control for the underlying condition exists, and confounding may persist despite advanced methods for adjustment (Bosco et al. 2010) . For example, proton pump inhibitors might produce an apparent increase in risk of gastrointestinal bleeding. This apparent increase could arise because that class of drugs is used to treat symptoms that might also be indicative of such bleeding. A predisposition for healthcare utilization can also produce confounding, perhaps because of functional status, or of access due to proximity, economic, and institutional factors (Brookhart et al. 2010b ). An additional concern is immortal time bias, whereby outcomes are not observable within the defined time at risk (Rothman & Suissa 2008; Suissa 2007 Suissa , 2008 .
Several strategies exist for reducing the effects of bias within observational database studies. These include design-level considerations and analysis approaches. Multiple study design approaches have been proposed for observational investigations, including cohort, case control, and self-controlled case series (SCCS), each with its own approach to address confounding. Selfcontrolled designs aim to address the threat of between-person confounding by comparing exposed and unexposed time at the individual level (Whitaker et al. 2006) . Confounders (e.g., sex) that do not change over time within a person are inherently controlled in such designs. Cohort designs compare outcome rates across populations, so they must control confounding by measuring and adjusting for confounding factors that vary among patients. Some believe each design may have potential applications for examining specific types of associations based on the attributes of the exposure and outcome (e.g., certain designs are presumed to be appropriate for short-term effects) (Gagne et al. 2012) .
Cohort studies, perhaps the most commonly used design, allow many possible approaches to address confounding. One design strategy is to impose restrictions on the selected sample to increase validity, potentially at the expense of precision. These restrictions are quite analogous to those employed in clinical trials and include ensuring that only incident drug users are studied; the restrictions also ensure similar comparison groups, patients without contraindications, and comparable adherence, as demonstrated by Schneeweiss et al. (2007) , who showed how bias was reduced at each stage of restriction using statin and 1-year mortality as an example.
The restriction to incident users deserves special attention, as implementation of a new-user design can eliminate prevalent user bias (Cadarette et al. 2009 , Ray 2003 , Schneeweiss 2010 . Within a new-user design framework, measures of association focus on events occurring after the first initiation of treatment, thus allowing a more direct comparison with an analogous group using an alternative treatment. The design can be logically extended to study drug switching and add-on therapies, as long as incident use of the target drug is preserved (Schneeweiss 2010) .
Comparator selection is also an important design consideration to reduce confounding by indication. The comparator definition should ideally yield patients in the same health circumstance as those eligible to be new users of the target medication. Frequently, when assessing a drug safety issue, the comparator is chosen to represent the standard of care that would have been provided to that patient had the person not been prescribed the target drug, such that relative effect estimates represent risk above and beyond what the patient could otherwise expect. However, a comparator may also be selected specifically to address a question about difference in risk stemming from the underlying biological mechanism (for example, choosing a comparator drug with the same indication). A challenge in comparator selection arises either when no standard of care exists or when significant channeling bias to a particular drug class is present. For example, this bias might occur when a particular class of drugs is reserved for the most severely ill patients, who might be at increased risk for an adverse event because of the increased severity of disease. In this regard, evaluation studies can be highly sensitive to the comparator selected, and a criticism of these studies is often the subjective nature by which the comparator was selected.
Once a design is established, researchers can further reduce bias through analysis strategies, such as matching, stratification, and statistical adjustment. Variables commonly considered for adjustment are those for which the distribution at baseline differs between the exposed and unexposed populations, or those known to potentially influence treatment decisions. To produce confounding, these variables also need to be associated with outcome occurrence; they may include patient demographics (such as age, gender, and race) or patient comorbidities (expressed either as a set of binary classifiers of specific diseases or as a composite index of comorbidity). One commonly used measure is the Charlson index (Bravo et al. 2002; Charlson et al. 1987 Charlson et al. , 1994 Cleves et al. 1997; D'Hoore et al. 1993 D'Hoore et al. , 1996 Li et al. 2008; Needham et al. 2005; Quan et al. 2005; Southern et al. 2004; Zhang et al. 1999) , which was originally developed to predict mortality but has also been shown to be related to healthcare expenditures (Farley et al. 2006) . Adjustment for a comorbidity index is useful for exploratory data analysis (Schneeweiss et al. 2001 ) but may not suffice to address all sources of confounding. Additional variables often cited include prior use of medications and markers for health service utilization, such as number of outpatient visits and inpatient stays. The specific definitions and applications of covariates are highly variable across drug safety evaluation studies. Covariate selection can influence the magnitude of effect measures, regardless of the modeling approach undertaken, particularly if effect modification exists (Lunt et al. 2009 ).
Once variables are identified, one can control for them through direct matching or stratification, whereby the target and comparator groups are logically divided by the attributes of the covariates. However, in a multivariable context, the data may be too sparse to provide adequate sample size to allow matching on all covariates or to provide subpopulations within each covariate-defined stratum (i.e., there may be empty cells defined by combinations of covariates). A popular tool to overcome this limitation is propensity score analysis (Rosenbaum 2002 , Rubin 1997 .
As with other approaches, the propensity score model is only as good as the covariates selected to provide the adjustment. A propensity score is a single metric that is intended to account for all of the explanatory variables that predict who will receive treatment. Propensity scores generally balance observed confounders but do not necessarily produce balance on factors not incorporated into the model. Such imbalances represent a particular problem for the analysis of databases in which many important covariates, such as smoking status, alcohol consumption, body mass index, and lifestyle and cultural attitudes regarding health, are not captured. demonstrated that further adjustment could be achieved by conducting supplemental validation studies to collect additional information on previously unmeasured confounders. showed how unmeasured confounders biased estimates of COX-2 inhibitors and myocardial infarction. Seeger et al. (2003 Seeger et al. ( , 2005 Seeger et al. ( , 2007 highlighted how a model without the appropriate variables included could yield a biased estimate in a case study that explored association of statin therapy and myocardial infarction. Strategies for automated selection of large sets of covariates have been proposed as potential solutions to reduce the possibility of missing an empiric confounder ). Sensitivity analysis has been proposed as an additional approach to assess the potential consequences of unobserved confounding (Schneeweiss 2006) but is unfortunately rarely reported in published studies. For example, Rosenbaum (2002) posits the existence of a latent confounder and explores the magnitude of the confounding that would be required to explain away the observed effect.
Instrumental variable (IV) analysis presents another potential solution to adjusting for confounding through control of a factor that is related to exposure but unrelated to outcome (Brookhart et al. 2010a , Hogan & Lancaster 2004 , Schneeweiss 2007 . Several studies have shown how IV analysis can reduce bias (Dudl et al. 2009; Rassen et al. 2009 Rassen et al. , 2010 Schneeweiss et al. 2008) . A challenge in IV analysis is identifying a covariate that satisfies the criteria of an IV, particularly with regard to having no association with the outcome. For active surveillance, in which one may explore multiple outcomes for a given exposure, the selection of a common IV becomes even harder.
One consideration for all statistical adjustment techniques in drug safety evaluation studies is the danger of the statistical adjustment itself introducing bias. Statistical control can sometimes either increase bias or decrease precision without affecting bias and can thereby produce less reliable effect estimates (Schisterman et al. 2009 ). For example, bias can also be induced if an analysis improperly stratifies on a collider variable (Cole et al. 2010) , that is, a variable that is itself directly influenced by two other variables. As a result, care is necessary in any evaluation study to develop a parsimonious model that achieves an appropriate balance between bias and variance. Although researchers have made substantial progress to establish theoretical and conceptual arguments for design and analysis considerations in observational data analysis, very little empirical evidence exists to support best practice and determine how observational analyses should be properly interpreted when evaluating the potential effects of medical products.
EVALUATING THE PERFORMANCE OF METHODS: THE OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP EXPERIMENT
We have conducted a large-scale observational data experiment that seeks to empirically establish the operating characteristics of many standard epidemiologic methods. Specifically, we created a reference set of 399 product-outcome pairs, each classified as either a positive control (i.e., the product increases the risk of the outcome) or a negative control (i.e., the product neither increases nor decreases the risk of the outcome) . Across five databases, we assess how well hundreds of different analytic methods can (a) discriminate between the positive controls and the negative controls and (b) estimate the true relative risk for the negative controls.
Data and Test Cases
The five databases included in the work presented here are from Truven Health Analytics (formerly the health business of Thomson Reuters), specifically, from MarketScan R Lab Supplement (MSLR; 1.2 million people), Medicare Supplemental Beneficiaries (MDCR; 4.6 million people), Multi-State Medicaid (MDCD; 10.8 million people), Commercial Claims and Encounters (CCAE; 46.5 million people), and the Quintiles Practice Research Database (GE Centricity EHR; 11.2 million people). Quintiles is an EHR database, whereas the other four databases contain administrative claims data. Table 1 provides further details about each of the databases. All databases were transformed into a common data model using a standardized vocabulary, such that analyses could be consistently applied across the different sources We created a large series of positive and negative controls, known drug-outcome associations for four HOI: acute kidney injury, acute liver injury, acute myocardial infarction, and upper gastrointestinal bleeding [definitions are described in Hansen (2013) and available at http://omop.org/HOI]. These HOI represent four of the most important drug safety outcomes considered for a risk identification system (Trifirò et al. 2009 ). Their importance lies in their frequency of occurrence, in their clinical impact, or in both. For each of these outcomes, drugoutcome pairs were classified as positive controls (active ingredients with evidence to suspect a positive association with the outcome) or negative controls (active ingredients with no evidence to expect a causal effect with the outcome) based on the following criteria.
Positive Controls:
The event is listed in the boxed warning or warnings/precautions section of an active FDA Structured Product Label. The drug is listed as a "causative agent" in Tisdale & Miller (2010) . The literature review identified no adequately powered studies that refuted evidence of effect.
Negative Controls:
The event is not listed anywhere in any section of an active FDA Structured Product Label. The drug not listed as a causative agent in Tisdale & Miller (2010) . The literature review identified no adequately powered studies with evidence of potential positive association.
The test cases include 165 positive controls and 234 negative controls . The article describes the full set of test cases and provides a more detailed description of the manner in which we constructed the set. Note that for the positive controls, we have not attempted to characterize the true effect size, other than hypothesizing that this effect is positive.
Methods Evaluated
We sought to establish the operating characteristics of seven methods [new-user cohort, case control, SCCS, self-controlled cohort (SCC) (observational screening), disproportionality analysis (DP), information component temporal pattern discovery (ICTPD), and longitudinal gamma Poisson shrinker (LGPS)]. Table 2 provides a description of each method, as well as the specific implementation choices considered within each method. We believe these methods include all commonly used approaches in observational studies of healthcare.
For each analytic method and combination of analytic design choices, we generated estimated relative risks and associated standard errors for all 399 drug-outcome test cases. The estimates and associated standard errors for all of the analyses are available for download at http://omop.org/Research. For every database, we considered only those drug-outcome pairs with sufficient power to detect a hypothetical relative risk of 1.25, based on the age-by-genderstratified drug and outcome prevalence estimates (i.e., the power calculations were based on marginal distributions, not on observed associations).
Metrics
To gain insight into the ability of a method to distinguish between positive and negative controls, we used the effect estimates to compute the area under the receiver operating characteristic curve (AUC) (Fawcett 2006) , a measure of predictive accuracy: An AUC of 1 indicates a perfect prediction of which test cases are positive and which are not. An AUC of 0.5 is equivalent to random guessing. distribution with variance = 1, Laplace prior distribution with variance = 1; High-dimensional propensity scoring (HDPS): 100 top confounders from among 200 most prevalent covariates in each dimension that occur in at least 100 persons, 500 top confounders from among 500 most prevalent covariates in each dimension that occur in at least 100 persons Propensity score trimming: none, trim lower 5% from the comparator group and the upper 5% from the target group Metric: propensity score adjustment using propensity score as continuous variable in logistic regression outcome model, propensity score adjustment using 5 strata as indicator variables in logistic regression outcome model, propensity score adjustment using 20 strata as indicator variables in logistic regression outcome model, propensity score stratification using Mantel-Haenszel adjustment over 5 strata, propensity score stratification using Mantel-Haenszel adjustment over 20 strata, unadjusted odds ratio from univariate logistic regression predicting outcome from exposure Combinations to be tested: 126 
Longitudinal gamma Poisson shrinker (LGPS)
LGPS applies Bayesian shrinkage to an estimated incidence rate ratio to compare the exposed population with the general population, and LEOPARD aims to detect and discard associations due to protopathic bias. Often not only are we interested in whether there is an effect, but also we would like to know the magnitude of the effect. However, to evaluate the accuracy of the effect size estimates for a particular analytic method, we must know the true effect size. This true effect size is never known, so we restrict our analysis to the negative controls, for which we assume that the true log relative risk is zero. Using the negative controls in real data, we compute bias, the average difference between the observed log relative risk and zero. An unbiased estimator would yield a bias of zero. The mean squared error (MSE) (Pladevall et al. 1996) is the average squared difference between the log relative risk and zero. Because zero is the true log relative risk, smaller MSEs are desirable. Coverage probability is the fraction of the 95% intervals that include zero. In the case of an unbiased estimator with valid confidence interval estimation, we would expect the coverage probability to be 95%. Table 3 presents the analytic method that provided the best AUC for each outcome-database combination as well as the associated AUC value. Each six-digit code specifies a particular set of design choices (for details, see the OMOP 2011-2012 Experiment Method Reference spreadsheet available at http://omop.org/Research). For every database-outcome combination, self-controlled methods (SCC, SCCS, and ICTPD) provide the optimal performance, with AUCs ranging from a low of 0.77 for acute liver injury in the MDCD database to 1.00 for acute kidney injury in the MSLR database. In general, AUCs are highest for acute kidney injury and lowest for acute liver injury, with acute myocardial infarction and gastrointestinal bleeding in between. Performance across the five data sources is similar despite their substantial differences in patient populations ( Table 1) . The case-control method, LGPS, and DP consistently underperform other methods, often yielding AUCs close to 0.5. Within each method, the specific design choices that correspond to the global optimum generally perform well for all outcomes and databases. Consider, for example, the SCC design; with the exception of acute myocardial infarction in MDCD, performance of the database-outcome optimum design choices does not exceed the global optimum by more than 0.10 in AUC. The design choices within each method affect performance significantly. Area under the receiver operating characteristic curve (AUC) values for all analytic methods, broken down by database and method. The solid lines represent the AUCs for the set of design choices within each method that provided the best performance on average across all outcomes and databases, a specific version of global optimum. Abbreviations: CC, case control; CCAE, MarketScan Commercial Claims and Encounters; CM, cohort method; DP, disproportionality analysis; GE, GE Centricity; ICTPD, information component temporal pattern discovery; LGPS, longitudinal gamma Poisson shrinker; MDCD, MarketScan Multi-State Medicaid; MDCR, MarketScan Medicare Supplemental Beneficiaries; MSLR, MarketScan Lab Supplemental; SCC, self-controlled cohort; SCCS, self-controlled case series.
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to 0.5, despite the existence of design choices with quite high AUC values for the same drug-outcome pair. Table 4 considers bias, MSE, and 95% confidence interval coverage for database-outcome optimal analytic methods. Because the true relative risks are unavailable for the positive controls, the table just draws on the negative control test cases. Table 4 shows that, in our experiments, the case-control, SCC, and LGPS methods generally yield positively biased effect estimates, whereas the cohort method generally yields negatively biased estimates. The SCCS method yields estimates that are close to unbiased. All three self-controlled methods produce smaller MSEs than the other methods, with SCCS being especially close to zero. No method provides coverage probabilities that are close to the nominal 95%. On average, coverage probabilities for the cohort, disproportionality, ICTPD, LGPS, and SCC methods are all below 50%. Average coverage for the case-control method is 63%, whereas for SCCS, the average coverage is 76%. Figure 2 presents the point estimates for the negative controls across all analysis methods. The positive bias of the case-control, SCC, and LGPS methods reveals itself, as does the negative bias of the cohort method. The smaller MSE associated with SCCS is also apparent.
Discussion of the Experimental Results
Although no method resulted in perfect discrimination, many methods were substantially better than random guessing. Optimum AUCs ranging from 0.76 to 0.94 seem promising and are at least as good as the predictive accuracy that is typically observed for diagnostic tests used in routine clinical practice. These results suggest that observational data can play an important role in the assessment of the effects of medical products, but no single analysis can provide definitive evidence.
Self-controlled designs (SCC, ICTPD, and SCCS) performed well across all 20 databaseoutcome scenarios. They generally outperformed case-control and new-user cohort designs in terms of predictive accuracy and did not exhibit notably different error distributions or bias.
All methods have poor coverage probability. This issue is related both to the bias in the point estimate (the difference between the point estimate and the true effect) and to underestimation of the standard error when generating the confidence intervals, and it may be systemic, plaguing the entire enterprise of observational database analysis. Part of the problem is understandable: Confidence intervals convey only error due to sampling variability around an unbiased estimator, but these databases provide extremely large samples that result in modest sampling variability. However, the true culprit in errant observational database studies is systematic error due to, for example, residual confounding and misclassification, which are not accounted for in traditional calculations. Furthermore, unlike sampling variability, systematic error does not diminish as sample size increases. The implication of this fact is that traditional statistical methods for controlling bias, e.g., covariate adjustment or matching, are failing, in these examples, to correct for bias.
Our results suggest that performance improvements result from customizing analyses to databases. Different databases represent different source populations and different data capture processes, and thus some sources might be better at addressing specific questions. Each database exhibits unique limitations that could affect performance. For example, owing to high turnover, payer-based claims data may provide shorter longitudinal capture, whereas outpatient EHR systems may have more incomplete capture during the observation period.
We have not established the generalizability of these findings. That we see different analyses yield the highest predictive accuracy for different database-outcome pairs suggests caution is necessary when projecting these results to other databases or to other outcomes. Further experiments are needed to determine the degree to which results can be generalized across outcomes. A possible direction is to conduct similar experiments for an additional 19 outcomes identified by the Exploring and Understanding Adverse Drug Reactions project (http://www.euadr-project.org) as high-priority safety issues (Trifirò et al. 2009 ).
Our analytic methods do not have access to the labels for the test cases, that is, whether a particular test case was a positive control or a negative control. Thus, our results are not optimistically biased in the sense they would be in a machine learning experiment that reported performance on training data. However, our results pertain to the specific 399 test cases that we studied, and generalizing to future test cases requires, at the very least, an exchangeability assumption that may or may not be reasonable.
CALIBRATING RESULTS
The experimental results in Section 2 demonstrate the possibility that typical observational studies may not account for all sources of bias leading to, for example, confidence intervals with poor coverage properties. Similarly, p-values from observational studies may mislead. For example, hypothesis tests with a nominal 5% α level may yield false positive rates that substantially depart from 5%. In this section, we explore this issue and present empirically calibrated p-values that GE  CCAE  MDCR  MDCD  MSLR  GE  CCAE  MDCR  MDCD  MSLR  GE  CCAE  MDCR  MDCD  MSLR  GE  CCAE  MDCR  MDCD  MSLR  GE  CCAE  MDCR  MDCD  MSLR  GE  CCAE  MDCR  MDCD  MSLR  GE  CCAE  MDCR  MDCD 
Relative risk
may support more appropriate inferences and decisions. The core idea is to derive an empirical null distribution using the negative control test cases described in Section 4.1.
Empirical Null Distributions
To demonstrate the empirical calibration, we selected three drug safety study exemplars from the literature representing a case-control, a cohort, and an SCCS design. We attempted to replicate these studies as best as we could but used databases different from those used in the original articles. The cohort study investigated the relationship between isoniazid and acute liver injury, whereas the case-control and SCCS studies investigated the association between sertraline and upper gastrointestinal bleeding. Our replications produced very similar effect estimates, each falling within the 95% confidence interval reported in the original article.
Next, we applied the same three designs to sets of negative controls: drugs that are not believed to cause the outcome of interest. Figure 3 shows the estimated odds ratios and incidence rate ratios, together with associated 95% confidence intervals. As is evident in Figure 3 , traditional significance testing fails to capture the diversity in estimates that exists when the null hypothesis is true. Although all the featured drug-outcome pairs are negative controls (i.e., assumed to have a true odds ratio or rate ratio of 1), a large fraction of the null hypotheses are rejected. We would expect only 5% of negative controls to have p < 0.05. However, in Figure 3a (cohort method), 17 of the 30 negative controls (57%) are either significantly protective or significantly harmful. In Figure 3b (case-control method), 33 of 46 negative controls (72%) are significantly harmful. Similarly, in Figure 3c (SCCS method), 33 of 45 negative controls (73%) are significantly harmful, although not the same 33 as in Figure 3b .
These numbers cast doubts on any observational study that would claim statistical significance. Consider, for example, the odds ratio of 2.4 that we found for sertraline using the case-control method; we see in Figure 3b that many of the negative controls have similar or even higher odds ratios. The estimate for sertraline was highly significant ( p < 0.001), meaning the null hypothesis can be rejected based on the usual theoretical model, i.e., assuming a null distribution centered at a relative rate of 1.0. However, based on the empirical distribution of negative controls, we can argue that we should not reject the null hypothesis so readily.
Calibration
Using the empirical distributions of negative controls, we can compute a better estimate of the probability that a value at least as extreme as a certain effect estimate could have been observed under the null hypothesis . Figure 4 shows the fraction of negative controls for which the p-value is below α for every level of α, for both the traditional p-value calculation and the calibrated p-value using the empirically established null distribution. For the calibrated p-value, a leave-one-out design was used: For each Point estimates for the negative controls across all analysis methods. Red dots indicate estimates for which the corresponding 95% confidence interval does not include one, whereas blue dots indicate estimates for which the corresponding 95% confidence interval includes zero (i.e., a relative risk of one on the original scale; in an ideal situation, with unbiased estimators, 95% of all dots should blue Calibration plots, showing the fraction of negative controls with p < α for different levels of α. Both traditional p-value calculation (dashed lines) and p-values using calibration (solid lines) are shown. For the calibrated p-value, a leave-one-out design was used. Abbreviations: GE, GE Centricity; MDCR, MarketScan Medicare Supplemental Beneficiaries; SCCS, self-controlled case series.
negative control, the null distribution was estimated using all other negative controls. A wellcalibrated p-value calculation should follow the diagonal: For negative controls, the proportion of estimates with p < α should be approximately equal to α. Most significance testing uses an α of 0.05, and we see in Figure 4 that the calibrated p-value leads to the desired level of rejection of the null hypothesis. For the cohort, case-control, and SCCS methods, the number of significant negative controls after calibration is 2 of 34 (6%), 5 of 46 (11%), and 3 of 46 (5%), respectively.
Applying the calibration to our three example studies, we find that only the cohort study of isoniazid reaches statistical significance ( p = 0.01). The case-control and SCCS analyses produced p-values of 0.71 and 0.84, respectively. Note that the calibration process could theoretically result in a larger p-value although we have not seen this happen in practice. Figure 5 shows a graphical representation of the calibration. By plotting the effect estimate on the x-axis and the standard error of the estimate on the y-axis, we can visualize the area where the traditional p-value is smaller than 0.05 (the gray area below the dashed line) and where the calibrated p-value is smaller than 0.05 (orange area). Many of the negative controls fall within the gray area, indicating a traditional p < 0.05, but only a few fall within the orange area, indicating a calibrated p < 0.05.
Visualization of the Calibration
In Figure 5a , the drug of interest, isoniazid, is clearly separated from the negative controls, and this separation is the reason why we feel confident we can reject the null hypothesis of no effect. In Figure 5b ,c, the drug of interest, sertraline, is indistinguishable from the negative controls. These studies provide little evidence for rejecting the null hypothesis.
A RECIPE FOR OBSERVATIONAL STUDIES
Current strategies for the design of observational studies rely heavily on the expertise of analysts. A process of expert consideration, introspection, anecdote, and discussion leads to a particular Traditional and calibrated significance testing. Estimates below the dashed line ( gray area) have p < 0.05 using traditional p-value calculation. Estimates in the orange areas have p < 0.05 using the calibrated p-value calculation. In each panel, blue dots indicate negative controls, whereas the yellow diamond indicates the particular drug of interest: (a) isoniazid and (b,c) sertraline. Abbreviations: GE, GE Centricity; MDCR, MarketScan Medicare Supplemental Beneficiaries; SCCS, self-controlled case series.
design. The consumer of the resulting analysis must rely on the professional experience and reputation of the analyst to assess the weight of evidence to attach to the study. Because little empirical evidence exists to support this process, the subjective assessment of new results, along with prior beliefs about the reliability of observational studies, dominates the interpretation of observational findings in current practice. Our work suggests an alternative path that provides a data-driven approach to study design. We found that all methods have error, and the magnitude/direction of error varies by analysis and database. Although some analyses carried substantial information, with AUC > 0.80, considerable bias and large MSE existed, with p-values and confidence intervals far from nominal operating characteristics. Future work can lead to improvements in methods that may have better performance, but our findings suggest that empirical evidence will be required to justify interpreting observational analyses properly. However, we also found that the empirical evidence generated can be used to improve the operating characteristics through calibration. Suppose an analyst wishes to study the association between intervention I and outcome O in observational database D. We tentatively recommend proceeding as follows:
1. Develop a set of test cases for O. That is, identify a set of positive control interventions that are known to be associated with O and a set of negative control interventions that are known to be unassociated with O. 2. Run every possible study design in D to generate design-specific estimates and standard errors for all test cases. 3. Choose the study design that optimizes some desired combination of AUC, MSE, bias, and coverage. 4. Report calibrated p-values (and, in due course, calibrated confidence intervals) for the optimal design along with the performance characteristics associated with the design, as computed in step 3. 5. As a sensitivity exploration, report calibrated confidence intervals and p-values for the other high-performing designs along with their performance characteristics.
Whether such an approach yields better results than the current expert-centric strategy remains unknown. A key limitation of our recipe is that it is specific to the database and to the outcome only. Future work will consider extensions that also account for characteristics of the target drug.
DISCUSSION
We have demonstrated the empirical performance of various analytic methods for observational studies across a range of database-outcome combinations. The ability of an analytic method to discriminate between positive and negative test cases, rather than the more traditional subjective judgment of an expert analyst, dictates the customization. No method resulted in perfect discrimination, but many methods were substantially better than random guessing. Section 4 reviewed a procedure for calculating calibrated p-values for observational studies. We have developed a related procedure for calculating calibrated confidence intervals that involves inverting the hypothesis test associated with the calibrated p-value. Thus, for example, the value zero is in the 95% calibrated confidence interval for the true log relative risk if the two-sided calibrated p-value exceeds 0.05. For values other than zero, we resort to injecting known relative risks into simulated data (see Murray et al. 2011 for a complete description of the simulation procedure).
We believe that the path forward for observational studies lies not only in more thoughtful and careful study design but also in augmenting current practice by applying a rigorous and empirically-driven systematic approach to study design. This approach considers observational studies as instruments for making measurements. Only by systematically measuring and comparing performance of well-characterized processes can we hope to improve our ability to measure the strength of association between drug exposure and outcome and to distinguish between positive and negative effects. If the process is thoughtful and careful but ad hoc, comparing its application across different problems is impossible, and therefore the process cannot be improved. As Popper (1965) has pointed out, "I knew, of course, the most widely accepted answer to my problem: that science is distinguished from pseudoscience-or from 'metaphysics'-by its empirical method, which is essentially inductive, proceeding from observation or experiment." Applying an empirically based approach to observational analysis offers tremendous potential for meaningfully and reliably contributing to the scientific evidence base needed to support medical practice. 
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